Geode Capital Management
FULC icon

Geode Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Geode Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24M Sell
1,432,133
-54,409
-4% -$331K ﹤0.01% 2888
2026
Q1 		$11.4M Buy
1,486,542
+380,729
+34% +$3.53M ﹤0.01% 2307
2025
Q4 		$12.5M Buy
1,105,813
+101,762
+10% +$1.04M ﹤0.01% 2294
2025
Q3 		$9.24M Sell
1,004,051
-189,087
-16% -$1.37M ﹤0.01% 2454
2025
Q2 		$8.21M Sell
1,193,138
-38,237
-3% -$205K ﹤0.01% 2481
2025
Q1 		$3.55M Sell
1,231,375
-63,140
-5% -$232K ﹤0.01% 2828
2024
Q4 		$6.09M Sell
1,294,515
-26,347
-2% -$97.2K ﹤0.01% 2646
2024
Q3 		$4.72M Buy
1,320,862
+13,485
+1% +$100K ﹤0.01% 2787
2024
Q2 		$8.11M Buy
1,307,377
+743,919
+132% +$5.64M ﹤0.01% 2455
2024
Q1 		$5.32M Buy
563,458
+10,228
+2% +$91.3K ﹤0.01% 2664
2023
Q4 		$3.74M Buy
553,230
+18,727
+4% +$83.1K ﹤0.01% 2846
2023
Q3 		$2.37M Sell
534,503
-31,306
-6% -$137K ﹤0.01% 3017
2023
Q2 		$1.87M Sell
565,809
-496,825
-47% -$1.46M ﹤0.01% 3132
2023
Q1 		$3.03M Buy
1,062,634
+206,802
+24% +$1.85M ﹤0.01% 2851
2022
Q4 		$6.23M Buy
855,832
+230,762
+37% +$1.5M ﹤0.01% 2538
2022
Q3 		$5.06M Buy
625,070
+58,557
+10% +$419K ﹤0.01% 2672
2022
Q2 		$2.77M Buy
566,513
+36,376
+7% +$355K ﹤0.01% 3002
2022
Q1 		$12.5M Buy
530,137
+32,132
+6% +$455K ﹤0.01% 2194
2021
Q4 		$8.81M Buy
498,005
+39,563
+9% +$784K ﹤0.01% 2540
2021
Q3 		$12.9M Buy
458,442
+101,850
+29% +$1.93M ﹤0.01% 2274
2021
Q2 		$3.74M Buy
356,592
+71,855
+25% +$726K ﹤0.01% 3068
2021
Q1 		$3.35M Buy
284,737
+77,067
+37% +$953K ﹤0.01% 2981
2020
Q4 		$2.43M Buy
207,670
+59,587
+40% +$674K ﹤0.01% 2976
2020
Q3 		$1.17M Buy
148,083
+21,961
+17% +$264K ﹤0.01% 3145
2020
Q2 		$2.31M Buy
126,122
+5,720
+5% +$90.1K ﹤0.01% 2764
2020
Q1 		$1.44M Buy
120,402
+61,701
+105% +$987K ﹤0.01% 2849
2019
Q4 		$976K Buy
58,701
+30,910
+111% +$295K ﹤0.01% 3285
2019
Q3 		$184K Buy
+27,791
New +$307K ﹤0.01% 3801

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's FULC Position: Q2 2026 in Review

Geode Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 3.7% in Q2 2026, selling an estimated $331K and leaving 1,432,133 shares worth $5.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2888.

Geode Capital Management first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $12.9M in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Geode Capital Management held 1,432,133 shares of Fulcrum Therapeutics worth $5.24M as of Q2 2026.
  • Geode Capital Management sold 54,409 Fulcrum Therapeutics shares in Q2 2026, an estimated $331K.
  • Fulcrum Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2888 holding.
  • Geode Capital Management first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Geode Capital Management's Fulcrum Therapeutics position peaked at $12.9M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.